MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$30,974K
EPS
-$0.48
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development
14,290
General and administrative
5,795
Total operating expenses
20,085
Total operating loss
-20,085
Interest income
126
Interest expense
7,329
Change in fair value of derivatives
-3,548
Total other expense
-10,751
Net loss
-30,836
Preferred stock dividends
138
Net loss applicable to common stockholders
-30,974
Basic EPS
-0.48
Diluted EPS
-0.48
Basic Average Shares
63,903,000
Diluted Average Shares
63,903,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss applicableto common...-$30,974K Net loss-$30,836K Preferred stock dividends$138K Total operating loss-$20,085K Total other expense-$10,751K Interest income$126K Total operatingexpenses$20,085K Interest expense$7,329K Change in fair value ofderivatives-$3,548K Research and development$14,290K General andadministrative$5,795K

GALECTIN THERAPEUTICS INC (GALT)

GALECTIN THERAPEUTICS INC (GALT)